NEW YORK (GenomeWeb News) – A consortium of research centers led by the Institute of Cancer Research, London will partner with Illumina to launch a new sequencing-based testing program to analyze genetic mutations in cancer patients, the Wellcome Trust said today.

Funded with £2.7 million ($4.1 million) from the Wellcome Trust, the Mainstreaming Cancer Genetics program will incorporate Illumina's TruSight Cancer panel into clinical care as part of a three-year pilot project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.